23.10.20: Not intended for U.S. and UK Media - Data from Phase III FIDELIO-DKD study presented at the American Society of Nephrology (ASN)'s Kidney Week 2020

Finerenone significantly reduced renal and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes Finerenone is a first-in-class investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist that demonstrated renal and cardiovascular benefits in patients with chronic kidney disease and type 2 diabetes / Finerenone specifically addresses MR overactivation, a key driver of disease progression / Despite guideline-directed therapies, patients with chronic kidney disease and type 2 diabetes remain at high risk of progression to kidney failure and cardiovascular events / Results from the FIDELIO-DKD study were simultaneously published in the New England Journal of Medicinemehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news